Health Care & Life Sciences » Biotechnology | Green Cross Holdings Corp.

Green Cross Holdings Corp. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
938,298
1,044,768
1,132,877
1,354,466
1,465,489
1,548,715
Cost of Goods Sold (COGS) incl. D&A
647,513
719,302
777,756
977,466
1,070,500
1,163,908
Gross Income
290,785
325,467
355,121
377,000
394,989
384,807
SG&A Expense
193,958
211,105
242,109
274,122
280,333
333,118
EBIT
94,773
111,975
110,367
99,255
111,925
49,312
Unusual Expense
387
24,931
17,496
715
8,601
15,348
Non Operating Income/Expense
23,183
34,291
34,507
10,600
4,080
12,316
Interest Expense
6,713
9,187
9,476
11,254
13,818
17,553
Pretax Income
112,134
113,169
119,727
99,601
96,146
43,189
Income Tax
27,916
38,604
44,124
25,700
25,418
23,810
Equity in Affiliates
3,427
26,904
37,246
363
-
-
Consolidated Net Income
80,791
101,469
112,849
74,264
70,728
19,379
Net Income
43,550
56,761
65,421
47,177
43,364
18,467
Net Income After Extraordinaries
43,550
56,761
65,421
47,177
43,364
18,467
Net Income Available to Common
43,550
56,761
65,421
47,177
43,364
18,467
EPS (Basic)
966.55
1,244.85
1,438.97
1,039.00
955.00
406.74
Basic Shares Outstanding
45
46
45
45
45
45
EPS (Diluted)
966.55
1,244.85
1,438.97
1,039.09
955.12
406.74
Diluted Shares Outstanding
45
46
45
45
45
45
EBITDA
115,225
138,020
141,873
134,354
153,169
96,594
Other Operating Expense
2,054
2,387
2,645
3,623
2,732
2,377
Non-Operating Interest Income
1,278
1,021
1,824
1,716
2,165
2,859
Minority Interest Expense
37,241
44,708
47,428
27,087
27,364
912
Equity in Affiliates (Pretax)
-
-
-
-
394
5,538

About Green Cross Holdings

View Profile
Address
107 Ihyeon-ro 30beon-gil
Yongin GY 16924
Korea, Republic Of
Employees -
Website http://www.greencross.com
Updated 07/08/2019
Green Cross Holdings Corp. is a holding company of Green Cross Corp. that engages in the manufacture of pharmaceutical products. It establishes and coordinates business strategies for Green Cross subsidiaries that launch business and investment portfolio management. Its products include prescription drugs such as blood derivatives, cerebrovascular disease treatment, fibrinolytic agent, vaccines, hunter syndrome drug, herbal medicine, and recombinant.